Breaking News

Longhorn Presents Advantages of Single Peptide Vaccine for Coverage of Human and Avian Influenza Viruses

April 2, 2024 • 9:54 am CDT
Longhorn Vaccines and Diagnostics 2024
(Precision Vaccinations News)

Longhorn Vaccines and Diagnostics today announced it is presenting a poster at the World Vaccine Congress on a mice study that examined LHNVD-110, a novel, unconjugated single peptide vaccine candidate comprised of multiple epitopes to broadly target human and influenza viruses. 

According to the Company's press release on April 2, 2024, results from the poster show that LHNVD-110 generated broadly reactive antibodies to human and highly pathogenic avian influenza (HAPI) viruses while neutralizing seasonal and pandemic influenza strains.

The Company says using a single peptide provides a more cost-effective and easily scalable approach to such a universal influenza vaccine.

In this study, Longhorn examined mice that were immunized intramuscularly with a low dose (2 µg) and high dose (20 or 40 µg) of LHNVD-110, an unconjugated composite influenza peptide vaccine with multiple highly conserved epitopes of HA, NA, and matrix (M1/M2/M2e), including a universal T cell epitope.

Two booster immunizations were given on days 21 and 35. Isotype specific IgG titers to composite peptides, individual epitopes, and multiple strains of influenza A (H1N1, H3N2, H5N1), and B (Yamagata, Victoria) were analyzed by an enzyme-linked immunosorbent assay, known as ELISA.

This data mirrors previous studies with LHNVD-105, a dual peptide vaccine containing the same epitopes.

"We are studying a single peptide universal influenza vaccine because we believe it could deliver a cost-effective strategy towards formulation and manufacturing and provide immunity against human and avian influenzas," said Longhorn Vaccines and Diagnostics CEO Gerald W. Fischer, MD, in a press release.

"We are expediting IND-enabling studies of LHNVD-110 to prepare for human clinical trials."

The Company wrote, 'While traditional influenza vaccines protect against specific strains predicted for circulation during the upcoming flu season, this often leads to mismatches and variable effectiveness. That is why peptide-based vaccines with broad strain coverage may offer useful strategies for preventing influenza, no matter the strain.'

LHNVD-110 is also formulated with the AddaVax™ adjuvant from InvivoGen.

Our Trust Standards: Medical Advisory Committee